Major PIPE Deals Propel Apollomics Shares 29.5% Amid Board Reshuffle

Introduction

Apollomics Inc (ticker: APLM) is a biotechnology company listed on the Nasdaq (NAS). As of September 17, 2025, the share price was $15.7750, reflecting a 29.52% increase, on a trading volume of 155,266 shares. The company, founded in 2015 and headquartered in Foster City, California, develops oncology combination therapies that engage the immune system and target specific molecular pathways.

Corporate Structure

Apollomics employs between 51 and 200 individuals across research, clinical development, and corporate functions. Its leadership team includes Guo-Liang Yu, PhD, co-founder, chairman, and chief executive officer, who has over 31 years of experience in the pharmaceutical and academic research sectors, and Matthew Plunkett, PhD, chief financial officer, who has led multiple biopharma initial public offerings and financing rounds.

Biotechnology by Sangharsh Lohakare

Recent Developments and News

On September 5, 2025, Apollomics filed a Schedule 13G/A (CIK: 0001944885) disclosing that Maxpro Investment Co., Ltd. held 105,071 Class A ordinary shares, representing approximately 4.90% of the class. On September 7, a Form 6-K report announced board appointments effective September 4, 2025, which included the formation of Audit, Compensation, and Nominating committees. On September 9, 2025, a Schedule 13D filing detailed that Hung-Wen Chen and King Regent Management Limited each acquired beneficial ownership of 896,362 shares, signifying ownership of 41.8% of Class A, through private investments in public equity (PIPE) transactions.

Financial and Strategic Analysis

The 41.8% ownership by these major stakeholders indicates concentrated voting power that may influence corporate governance and strategic direction. The PIPE agreements signed on September 2, 2025, provided new funding intended for clinical development and expansion of the oncology pipeline. Apollomics’ CFO has a track record of raising over $445 million through initial public offerings and financing deals, which suggests ongoing access to capital markets, essential for late-stage trials and potential partnerships.

Market Position and Industry Context

Apollomics focuses on ten drug candidates across 12 programs categorized as tumor inhibitors, anti-cancer enhancers, and immuno-oncology agents. Its dual operations in the U.S. and China allow the company to leverage regulatory and research partnerships in two significant biotechnology markets. As combination therapies gain relevance in oncology, Apollomics’ strategy involving integrated immune and molecular targeting positions it among biotechs pursuing differentiated treatment regimens.

TL;DR

From September 5–9, 2025, Apollomics reported share acquisitions from Maxpro Investment (4.90% stake) and a combined 41.8% stake from Hung-Wen Chen and King Regent Management, alongside board restructuring effective September 4. The share price increased by 29.52% to $15.7750. PIPE transactions are intended to fund ongoing clinical trials across Apollomics’ 12-program oncology pipeline.